Fuse Vectors has raised $5.2M in pre-seed financing led by HCVC for its cell-free viral vector technology. The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies.
Fuse Vectors is a biotechnology company specializing in the development of a novel, infinitely scalable gene therapy manufacturing platform. Founded in 2022 and based in Copenhagen, Denmark, the company aims to streamline and scale the production of viral vector-based gene therapies, particularly those utilizing Adeno-Associated Virus (AAV) vectors.
By integrating these technologies, Fuse Vectors aims to reduce manufacturing time and costs, enhance the safety and efficacy of gene therapies, and make these treatments more accessible to patients with various genetic disorders. The company's mission is to unlock access to gene therapies for everyone in need, delivering superior therapies swiftly to meet urgent patient needs.
"Fuse Vectors' cell-free Fuse Technology offers significant improvements, reducing production time and costs while enhancing vector quality to meet patients' unmet needs," said Benjamin Blaha, co-founder of Fuse Vectors.
"The enzymatic AAV capsid filling process eliminates cell-based AAV production, using efficient technologies that store components in a module library. This allows on-demand, controlled biocatalytic reactions to fill capsids and works across all serotypes."
"This investment from HCVC is a pivotal step for Fuse Vectors, bringing our pre-seed financing to 5 million EUR," said Henrik Stage, co-founder and Executive Chair of Fuse Vectors.
"We are excited to work towards our vision of making gene therapy more efficient, cost-effective, and accessible, and are grateful for the early support and financing received from BioInnovation Institute, EIFO and Innovation Fund during our ideation and start-up phase."
Currently in alpha testing, Fuse Vectors is collaborating with over half a dozen partners, from academic research groups to leading pharmaceutical companies. The company plans two commercialisation strategies: partnering with pharmaceutical companies, biotech firms, and academic institutions.
Would you like to write the first comment?
Login to post comments